Screener
ImmunityBio, Inc. IBRX Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Leasehold improvements | $73,277 | $73,141 |
| Equipment | 64,852 | 63,259 |
| Construction in progress | 86,433 | 86,433 |
| Furniture & fixtures | 1,857 | 1,867 |
| Software | 2,111 | 2,049 |
| Gross property, plant and equipment | 228,530 | 226,749 |
| Less: Accumulated depreciation and amortization | 115,745 | 112,485 |
| Property, plant and equipment, net | $112,785 | $114,264 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s cumulative cost basis?
- ImmunityBio, Inc. (IBRX) reported cumulative cost basis of $228.53M in Q1 2026.
- How has ImmunityBio, Inc.'s cumulative cost basis changed year-over-year?
- ImmunityBio, Inc.'s cumulative cost basis decreased by 4.1% year-over-year, from $238.21M to $228.53M.
- What is the long-term trend for ImmunityBio, Inc.'s cumulative cost basis?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s cumulative cost basis has grown at a 32.4% compound annual growth rate (CAGR), from $55.69M to $226.75M.
Ask your AI about ImmunityBio, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude